Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
1 - 10 of 61
- Intracellular dipeptidyl peptidase 9 (DPP9) interactions in primary human blood cells: how are they influenced by novel DPP9 inhibitors and PROTACs?From1 Nov 2022 → TodayFunding: FWO fellowships
- Improved FAP-radiotheranostics for personalized cancer treatment.From1 Oct 2022 → TodayFunding: BOF - doctoral mandates
- Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment (OncoProTools).From1 Sep 2022 → TodayFunding: Horizon Europe - Marie Skłodowska-Curie-actions
- Selective inhibitors of dipeptidyl peptidase 9 (DPP9) for induction of inflammatory cell death (pyroptosis) in cancer cells.From1 Sep 2022 → TodayFunding: IOF - technology concept exploration
- Development of theranostic ligands for fibroblast activation protein with improved pharmacokinetic profile.From1 Sep 2022 → TodayFunding: IOF - technology validation in lab
- Biomarker and therapy development through in vivo Molecular Imaging of small animals.From1 Jun 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Discovery of highly selective inhibitors and activity-based probes for dipeptidyl peptidase 9 (DPP9).From1 Nov 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Treatment of autophagy deficits in Charcot-Marie-Tooth disease caused by mutations in the small heat shock proteins HSPB1 and HSPB8.From1 Jan 2021 → TodayFunding: FWO research project
- The role of dipeptidyl peptidase 9 (DPP9) in human monocyte-derived macrophages: Discovery of DPP9 binding partners & natural substrates using novel chemical and cellular tools.From1 Jan 2021 → TodayFunding: FWO research project
- Validation of autophagy induction as a therapeutic strategy: from drug discovery and preclinical evaluation to safety investigation and biomarker research.From1 Jan 2021 → TodayFunding: BOF - projects
Publications
1 - 10 of 120
- Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valérie M.Y. Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Paula Frans Van Der Veken
Pages: 1 - 16 - Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients(2022)
Authors: An Bracke, Emilie De Hert, Michelle De bruyn, Karen Claesen, Gwendolyn Vliegen, Alexandra Vujkovic, Lida van Petersen, Fien De Winter, An Hotterbeekx, Isabel Brosius, et al.
Pages: 4 - 11 - Strecker-type reactions and MSAS as tools for protease inhibitor discovery(2021)
Authors: Pedro Santos Gonçalves, Pieter Paula Frans Van Der Veken, Koen Augustyns
Number of pages: 219 - Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics(2021)
Authors: Euy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Sarah Stephan, An Bracke, Pieter Paula Frans Van Der Veken, Ingrid De Meester, Frank Roesch
Pages: 476 - + - In vitro evaluation of the squaramide-conjugated fibroblast activation protein inhibitor-based agents AAZTA5.SA.FAPi and DOTA.SA.FAPi(2021)
Authors: Euy Sung Moon, Yentl Van Rymenant, Sandeep Battan, Joni De Loose, An Bracke, Pieter Paula Frans Van Der Veken, Ingrid De Meester, Frank Rösch
- In vitro and in situ activity-based labeling of fibroblast activation protein with UAMC1110-derived probes(2021)
Authors: Yentl Van Rymenant, Muhammet Tanc, Roos Van Elzen, An Bracke, Olivier De Wever, Koen Augustyns, Anne-Marie Lambeir, Mark M. Kockx, Ingrid De Meester, Pieter Paula Frans Van Der Veken
- Computational investigation of the catalytic mechanism and dynamics of Staphylococcus aureus glycosyltransferase towards development of novel antibiotics(2021)
Authors: Kenneth Goossens, Hans De Winter, Pieter Paula Frans Van Der Veken
Number of pages: 336 - Molecular imaging of apoptosis(2021)
Authors: Lucas Beroske, Tim Van den Wyngaert, Sigrid Stroobants, Pieter Paula Frans Van Der Veken, Filipe Elvas
- The effect of a novel serine protease inhibitor on inflammation and intestinal permeability in a murine colitis transfer model(2021)
Authors: Hanne Van Spaendonk, Hannah Ceuleers, Annemieke Smet, Maya Berg, Jurgen Joossens, Pieter Paula Frans Van Der Veken, Sven Francque, Anne-Marie Lambeir, Joris De Man, Ingrid De Meester, et al.
Pages: 1 - 13
Patents
1 - 10 of 10
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- KLK4 inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)